Protein chemistry / Proteomics

#Analysis #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Phenotypic Drug Discovery With High Content Screening

Phenotypic Drug Discovery With High Content Screening Sponsored by PerkinElmer Early drug discovery used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system - cells, tissue, or organisms - and asking the question, did this entity affect the phenotype? Target Based or Phenotypic… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Molecular medicine #Oncology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology

Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology Sponsored by Agilent This white paper discusses targeting energy metabolism for cancer therapeutic discovery using Agilent Seahorse XF technology. Abstract Altered energy metabolism is now recognized as a driver in many diseases. In cancer research, significant advances have… Read More

#Archive

#Biomarkers #Cell therapy #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Protein chemistry / Proteomics #RNA #Screening #Therapeutics

PhoreMost enters collaboration with Otsuka

PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical. PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project collaboration with Otsuka Pharmaceutical Co., the world-leading pharmaceutical company dedicated to the research and development of highly-innovative… Read More

#News

#Clinical specialities #Immunology / Virology & Vaccines #Protein chemistry / Proteomics #Therapeutics

Miltenyi Biotec launches tool for coronavirus-specific T cell research

Miltenyi Biotec has launched its SARS-CoV-2 PepTivator Peptide Pools, a new addition to its PepTivator Portfolio specifically developed to help researchers currently investigating COVID-19 Based on decades worth of experience in developing products for virus-specific T cell research, SARS-CoV-2 PepTivator Peptide Pools work by stimulating T cells specific… Read More

#Covid-19 #News

#Drug development #Drug discovery #Drug targets #Immunology #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Protein chemistry / Proteomics #RNA #Stem cells #Therapeutics #Translational #Translational chemistry

Pathios Therapeutics closes US$8.8M Series A and appoints Stuart Hughes as CEO

The financing will accelerate the development of first-in-class therapies in autoimmune disease and immuno-oncology. Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare… Read More

#News

#Analysis #Business #Lead discovery #Mass spectrometry / NMR #Metabolomics #Protein chemistry / Proteomics #RNA #Therapeutics

Thermo Fisher to showcase new products at Virtual ASMS Event

Thermo Fisher Scientific will provide online programming and virtual exhibits to introduce scientists to a number of new products that build on its leading Orbitrap platform and expand research applications. The company said it will showcase its newest instruments, software and workflow solutions during a company-hosted virtual event, vLC-MS.com,… Read More

#News

#Genomics #Lead discovery #Precision medicine #Protein chemistry / Proteomics

Biopharma R&D interest in quantum computing due to efficiency and effectiveness benefits

27 July 2020 Image: Michael Dziedzic New survey results from the Pistoia Alliance, the Quantum Economic Development Consortium (QED-C) and QuPharm show almost one third of life science organisations polled are set to begin quantum computing evaluation this year. A further 39% are planning to evaluate next year… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical specialities #Clinical trials #Drug discovery #High Content Screening #Immunology / Virology & Vaccines #Lead discovery #Protein chemistry / Proteomics #Therapeutics

PerkinElmer launches virtual open access Covid-19 Data Dashboards to accelerate research

The company has launched two online, free-to-access Covid-19 Data Dashboards to aid the global scientific community accelerate the discovery of antivirals and vaccines. The informatics tools are set to help scientists access, aggregate and analyse drug compound and clinical trial data and are powered by PerkinElmer’s data analytics… Read More

#Covid-19 #News

#Academic #Analysis #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Protein chemistry / Proteomics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Sphere Fluidics and Heriot-Watt University develop droplet generator instrumentation

20 July 2020 Image: Toa Heftiba Sphere Fluidics and Heriot-Watt University have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency. The grant will facilitate the development of novel droplet generator instrumentation, which will be used to expand Sphere Fluidics’ portfolio of… Read More

#News

#Assay development & optimisation #Automation / robotics #Biobanking #Business #Drug discovery #Genomics #Lead discovery #Oncology #Protein chemistry / Proteomics

SPT Labtech opens new office to maximise on Japanese biotech growth

15 July 2020 This is the company’s second site in the APAC region, headed by Masahiro Matsushita. The expansion follows long-standing partnerships with Japanese life science distributors. The move was motivated, in part, by growing biotech and healthcare markets in Japan. The increasing importance of the Japanese life… Read More

#News

#Analysis #Assay development optimisation & technology #Drug discovery #Protein chemistry / Proteomics #Sequencing #Target validation

Proteomics on NGS: Why this new launch could be a game changer

6 July 2020 Image: Science in HD Olink Proteomics’ Olink Explore 1536 combines the company’s proximity extension assay (PEA) high-multiplex immunoassay technology with next-generation sequencing (NGS) readout on the Illumina NovaSeq platform. Olink Explore 1536 has several features designed to overcome significant limitations in other proteomic technologies, including… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microfluidics #Molecular medicine #Nanomedicine / nanotechnology #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Therapeutics #Translational #Translational chemistry

Engineers use ‘DNA origami’ to identify vaccine design rules

30 June 2020 Image: Glen Carrie In lab tests, virus-like DNA structures coated with viral proteins provoke a strong immune response in human B cells, by Ann Trafton, MIT News Office By folding DNA into a virus-like structure, MIT researchers have designed HIV-like particles that provoke a strong immune… Read More

#News

#Animal models #Computational chemistry #Gene editing #Immunology #Protein chemistry / Proteomics #RNA #Therapeutics

Experimental peptide targets Covid-19

Computational modeling yields a protein fragment that could bind to coronavirus spike proteins and destroy them by Anne Trafton, MIT News Office The research described in this article has been published on a preprint server but has not yet been peer-reviewed by scientific or medical experts. Using computational models… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The CRISPR revolution arrives in immuno-oncology

The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 - Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered regularly-interspaced short palindromic repeats… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 - Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and… Read More

#Exclusive Content

#Animal models #Biologics / Biotechnology #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Oncology #Orphan drugs #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Therapeutics #Toxicology

ADCs and solid tumours – The payload revolution that drives therapeutic opportunities in unmet need

ADCs and solid tumours - The payload revolution that drives therapeutic opportunities in unmet need By Dr Jenny Thirlway Volume 21 Issue 2 - Spring 2020 The fight against cancer is ongoing. Despite progress in many indications, mortality rates for some of the most difficult to treat solid tumour types… Read More

#Exclusive Content